Over the past few years, messenger RNA (mRNA) has emerged as a transformative instrument in personalized medicine, particularly following the COVID-19 pandemic. Historically, personalized medicine has relied on the practice of designing therapies based on a patient’s genomic characteristics to provide the best treatment possible for a patient’s unique biological characteristics.
mRNA technology has remarkably increased the possibilities of precision drugs, not only in effectiveness but in opening the doors of its use to a larger set of diseases. For instance, in the case of lung cancer, a type of mRNA vaccine could be made to target only the specific neoantigens on tumor cells so that the immune system is educated to find and kill the cancer cells. It is also used in diseases such as cystic fibrosis (CF), which are caused by genetic mutations. mRNA can be effectively delivered using lipid nanoparticles (LNPs); by this means, mRNA has the potential to be the hero that will save the day by offering that “rescue” to the faulty CFTR proteins, which brings hope to personalized treatment for genetically related diseases.
mRNA Variants
Different mRNA Variants are being used in the development of precision/personalized medicine and are described below –
1. Messenger RNA (mRNA)
Directly encodes protein and is utilized in vaccines (such as COVID-19 vaccines) and gene therapy for inherited genetic disorders such as cystic fibrosis. mRNA may also be used in cancer immunotherapy, where mRNA encodes for tumor-specific neoantigens to instruct the immune system.
2. modRNA (Modified mRNA)
Like mRNA but with modifications to enhance stability and protein expression. Usually employed in vaccines and gene therapy to enhance therapeutic effect, particularly in cancer and infectious disease therapy.
3. saRNA (Self-Amplifying RNA)
Engineered to self-replicate within the body, with enhanced protein production at reduced doses. Applied in vaccines and cancer immunotherapy to elicit more sustained immune responses with less toxicity.
4. siRNA (Small Interfering RNA)
Applied to repress individual genes by breaking down target mRNA, aiding in the treatment of diseases resulting from overexpressing genes. Genetic disorders, cancer, and infections caused by viruses are major fields of use for siRNA to prevent the production of toxic proteins.
5. miRNA (MicroRNA)
Regulates gene expression by inhibiting mRNA translation or promoting degradation. It’s used in gene regulation therapies, cancer treatment, and controlling autoimmune diseases by modulating immune responses.
Watch our expert webinar on “mRNA’s Evolution from Vaccine to Next-Gen Therapeutics”-
The Imperative of Personalized Medicine: Transforming Healthcare through mRNA Technology
In the changing healthcare scenario, personalized medicine has become a cornerstone in delivering specifically designed treatments that address a patient’s genetic and biological makeup. Therefore, the most effective innovative strategy is the mRNA technology revolution for its use in the creation of patient-specific therapy, which is a major driver for the future of personalized therapies for several strong reasons that include –
- Rapid Design: mRNA is readily customizable according to patient-specific genomic information, allowing medical professionals to initiate timely and efficacious interventions specifically suited to the patient’s disease profile.
- Precise Protein Synthesis: By instructing cells to produce certain proteins, mRNA therapies allow effective treatment of advanced disease conditions such as cancer and infectious and genetic diseases. The precision implies a more direct attack on disease mechanisms, enhancing therapy results.
- Activation of Immune System: mRNA-based therapy possesses the distinctive capability to guide the immune system to recognize and fight against certain disease-inducing pathogens. Significantly, in oncology, where personalized mRNA vaccines can activate the immune response against tumor-specific neo-antigens.
- Adaptability and Flexibility: The inherent adaptability of the mRNA platform is easily incorporated into new infectious diseases, and hence, it is an extremely flexible tool in precision medicine. Its adaptability is also critical in addressing global health emergencies, including pandemics, where the speed of vaccine development is paramount.
Therefore, mRNA technology is at the cutting edge of personalized medicine, and it presents us with unparalleled potential to realize the vision of “one patient, one treatment.” With the ability of mRNA, we are not only treating disease; we are changing lives through precision-targeted therapies that promise a healthier tomorrow for patients everywhere.
Recent Breakthroughs in mRNA Therapeutics
- Neoantigen-Targeted Cancer Vaccines: mRNA platform may be exploited for the formulation of individualized cancer vaccines expressing patient-specific neoantigens for the activation and targeting of immune cells by distinct tumor cell lines effectively, like Moderna’s mRNA-4157/V940 therapy for coding up to 34 patient-specific neoantigens associated with a reduction of 44% in the occurrence of melanoma recurrence if paired with Keytruda (PD-1/PD-L1 axis targeting monoclonal antibody).
- CRISPR-mRNA Synergy: During synthetic mRNA-mediated delivery of CRISPR-Cas9 nucleases, researchers have attained a transient gene editing approach that fixes genetic disorders without making permanent changes to the DNA, thereby improving safety and efficacy.
- Organ-Specific Delivery Systems: Sophisticated lipid nanoparticles (LNPs) are designed to improve the targeted delivery of mRNA therapeutics. This facilitates the efficient treatment of diseases such as neurodegenerative diseases and cystic fibrosis by ensuring the delivery of mRNA to the targeted tissues.
- RNA Editing for Dynamic Therapy: mRNA-based RNA-guided editors, including ADAR enzymes, enable specific editing of erroneous RNA transcripts to offer a reversible therapy for genetic diseases without changing the underlying DNA
Key Companies and Platforms
- BioNTech’s FixVac Platformdeploys fixed combinations of mRNA-encoded non-mutated specific tumor antigens (e.g., NSCLC’s NY-ESO-1). For this platform, BioNTech collaborated with Regeneron to expand treatment for solid tumors (e.g., melanoma).
- ModernaTx, best known for its COVID-19 vaccines, also develops mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Additionally, the company has established partnerships with Merck to treat melanoma and non-small cell lung cancer (NSCLC) while integrating artificial intelligence to enhance neoantigen prediction.
- Strand Therapeutics developed programmable mRNA, an engineer’s self-replicating mRNA that activates only in diseased cells. A lead candidate, STX-001, targets IL-12 for treating melanoma and breast cancer, with Phase I trials underway.
- Anima Biotech priorities anAI platform, Lightning.Ai – which uses in-cell pathway visualization technology and high-throughput imaging to identify small molecules that modulate mRNA translation. Anima has a partnership with Takeda, Eli Lilly, and AbbVie, focusing on immunological diseases such as Fibrosis, Neuro Huntington, and Oncology.
- Alnylam Pharmaceuticals specializes in RNAi therapeutics and has developed effective small-interfering RNAs (siRNAs) delivered through lipid nanoparticles (LNPs). The company has several approved drugs, including Patisiran, a synthetic siRNA, and Vutrisiran, a double-stranded siRNA, both designed for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), a rare disease in adults.
The Path Ahead
The emergence of mRNA technology represents a genuine transformation in personalized medicine, providing a revolutionary framework for developing treatments by customizing therapies to incorporate individual genetic makeup. mRNA has the unique ability to encode specific proteins rapidly, creating new paradigms for treating conditions such as cancers and genetic diseases with extraordinary precision and efficacy. The adaptable nature of mRNA allows for the elevated effectiveness of treatments with reduced adverse effects. The future potential of mRNA is very exciting, along with other approaches such as self-amplifying RNA (saRNA) and personalized vaccines to revolutionize new treatment paradigms. As it advances and scales up, mRNA will bring health care globally, spearheading a new timeline for the prominence of precision medicine that improves patient outcomes worldwide.